Lung Transplant Rejection Clinical Trial
— DATACOLOfficial title:
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
NCT number | NCT04837339 |
Other study ID # | 2019_0015 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 17, 2022 |
Est. completion date | March 2037 |
Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.
Status | Recruiting |
Enrollment | 900 |
Est. completion date | March 2037 |
Est. primary completion date | March 2037 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: - Men or women over 15 years of age - Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant - Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent. - Be affiliated with a Health Insurance plan. Exclusion Criteria: - Pregnant, parturient and/or lactating woman - Hemoglobin level less than or equal to 8g/dl - Persons of full age who are subject to a legal protection measure or who are unable to express their consent - Persons under the protection of justice - Not being able to follow the study requirements for geographical, social or psychological reasons - Patient refusal. |
Country | Name | City | State |
---|---|---|---|
France | Roux | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate non-invasive markers of dysfunction to stratify the risk of rejection, present in the blood during the first year after transplantation (blood immunomarkers). | Correlation between blood biomarkers (cell free DNA, Donor Specific Antibodies characterization) and graft rejection. | 15 years | |
Secondary | Evaluate relevant gene sets associated with high or low risk profiles of acute dysfunction and rejection (intragraft expression). | Correlation of biomarkers (graft) with the functionality of the allograft | 15 years | |
Secondary | Stratify lung transplant recipients using non-invasive biomarkers and a gene expression profile for risk of allograft loss based on first year post-transplant data | Assessment of the risk of graft loss based on biomarker variations in repeated measurements. | 15 years | |
Secondary | Identify biomarkers and gene sets associated with response to immunosuppressive treatments of rejection | Correlation between gene expression in lung transplants and response to treatment of rejection | 15 years | |
Secondary | Evaluate the costs associated with the use of invasive and non-invasive strategies to define the risk of allograft rejection. | Costs incurred to define the risk of allograft rejection | 15 years | |
Secondary | Assessing patient acceptability and well-being using invasive and non-invasive biomarkers | Variation in patient well-being with the use of a non-invasive strategy to define the risk of allograft rejection | 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06309628 -
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
|
||
Withdrawn |
NCT02893176 -
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
|
Phase 4 | |
Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
Active, not recruiting |
NCT03967340 -
PREdiction of Chronic LUng Allograft Dysfunction
|
||
Active, not recruiting |
NCT05260372 -
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
|
||
Recruiting |
NCT06082037 -
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
|
Phase 3 | |
Recruiting |
NCT04714801 -
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05170425 -
LAMBDA 002 (Lung Registry) Study
|
||
Completed |
NCT02474927 -
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
|
Phase 2 | |
Recruiting |
NCT05006742 -
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT02812290 -
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
|
||
Not yet recruiting |
NCT03500575 -
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
|
N/A | |
Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
Completed |
NCT03359863 -
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
|
Phase 2 | |
Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
Completed |
NCT01985412 -
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
|
||
Completed |
NCT04234919 -
Longitudinal Study of Cell Free DNA in Lung Transplant
|
||
Recruiting |
NCT03090581 -
Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.
|
N/A | |
Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A |